VRX-0075
GLP-5 (quintuple agonist)
VRX-0075 is an investigational, long-acting "quintuple agonist" — a single molecule designed to activate five metabolic hormone receptors at once: GLP-1, GIP, glucagon, amylin and calcitonin. It is being developed by Volari Therapeutics and has been evaluated in Eli Lilly–supported research. The available evidence is exclusively preclinical (rodent); no human studies exist yet.
Key Facts: VRX-0075
Category
Weight Loss & Metabolic
Evidence
Preclinical
Availability
Research Only
Profile
Research profile
Research Overview & Mechanisms
VRX-0075 combines activity at five receptors in a single molecule. The first three — GLP-1, GIP and glucagon — are the same metabolic receptors targeted by triple agonists, involved in insulin secretion, satiety and energy expenditure. It additionally targets the amylin and calcitonin receptors, pathways linked to satiety and food-intake regulation. In preclinical in-vitro testing, its potency at the GLP-1/GIP/glucagon receptors was described as comparable to retatrutide, and at the amylin/calcitonin receptors as comparable to cagrilintide.
Reported Research Benefits
Frequently Asked Questions
FAQ
Clinical Evidence
Primarily animal studies and in-vitro data. Human clinical trials are limited or absent.
1
studies
Regulatory Status
VRX-0075 was presented as a late-breaking abstract (2839-LB) at the American Diabetes Association Scientific Sessions in 2026, by Volari Therapeutics in Eli Lilly–supported research. In preclinical models, its half-life was reported roughly 50% longer than semaglutide in rats, which the researchers considered consistent with possible weekly dosing. Obese rats showed a marked reduction in body weight, with no reported toxicology findings in a non-regulatory setting. Important limitation: animal weight-loss models routinely overstate the response later seen in humans, and tolerability — especially for an amylin-containing molecule — remains a critical open question. No human data exist.
Scientific Sources & Further Reading
Explore peer-reviewed research about VRX-0075:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →